Europe RNAi Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) Geography

No. of Pages: 136    |    Report Code: TIPRE00015148    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe RNAi Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe RNAi Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Europe RNAi Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 RNAi Therapeutics in Cancer Therapy
5.2 Market Opportunities
  • 5.2.1 Imaging Modalities for RNAi Therapeutics for RNAi Therapeutics
5.3 Future Trends
  • 5.3.1 Rising Research & Development (R&D) activity
5.4 Impact of Drivers and Restraints

6. Europe RNAi Therapeutics Market Regional Analysis

6.1 Europe RNAi Therapeutics Market Overview
6.2 Europe RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 Europe RNAi Therapeutics Market Forecast Analysis

7. Europe RNAi Therapeutics Market Analysis – by Molecule Type

7.1 Small Interfering RNAs
  • 7.1.1 Overview
  • 7.1.2 Small Interfering RNAs: Europe RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 MicroRNA
  • 7.2.1 Overview
  • 7.2.2 MicroRNA: Europe RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe RNAi Therapeutics Market Analysis – by Application

8.1 Genetic Disorders
  • 8.1.1 Overview
  • 8.1.2 Genetic Disorders: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oncology
  • 8.2.1 Overview
  • 8.2.2 Oncology: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Neurodegenerative Disorders
  • 8.3.1 Overview
  • 8.3.2 Neurodegenerative Disorders: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Cardiovascular
  • 8.4.1 Overview
  • 8.4.2 Cardiovascular: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Respiratory Disorders
  • 8.5.1 Overview
  • 8.5.2 Respiratory Disorders: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.6 Infectious Diseases
  • 8.6.1 Overview
  • 8.6.2 Infectious Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.7 Renal Diseases
  • 8.7.1 Overview
  • 8.7.2 Renal Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9. Europe RNAi Therapeutics Market Analysis – by Route of Administration

9.1 Intradermal Injections
  • 9.1.1 Overview
  • 9.1.2 Renal Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Pulmonary Delivery
  • 9.2.1 Overview
  • 9.2.2 Renal Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Intravenous Injections
  • 9.3.1 Overview
  • 9.3.2 Renal Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Intraperitoneal Injections
  • 9.4.1 Overview
  • 9.4.2 Renal Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10. Europe RNAi Therapeutics Market – Europe Analysis

10.1 Europe
  • 10.1.1 Europe RNAi Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
  • 10.1.1.1 Europe RNAi Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 UK: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.1.1 UK: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.1.2 UK: Europe RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.1.3 UK: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.2 Germany: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.2.1 Germany: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.2.2 Germany: Europe RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.2.3 Germany: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.3 France: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.3.1 France: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.3.2 France: Europe RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.3.3 France: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.4 Russia: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.4.1 Russia: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.4.2 Russia: Europe RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.4.3 Russia: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.5 Italy: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.5.1 Italy: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.5.2 Italy: Europe RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.5.3 Italy: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.6 Rest of Europe: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.6.1 Rest of Europe: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.6.2 Rest of Europe: Europe RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.6.3 Rest of Europe: Europe RNAi Therapeutics Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Europe RNAi Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Sanofi
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 GlaxoSmithKline plc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Silence Therapeutics
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Alnylam Pharmaceuticals, Inc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Arrowhead Pharmaceuticals, Inc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - E Market

  1. Sanofi
  2. GlaxoSmithKline plc
  3. Silence Therapeutics
  4. Alnylam Pharmaceuticals, Inc
  5. Arrowhead Pharmaceuticals, Inc
europe-rnai-therapeutics-market